Infliximab: a treatment option for ulcerative pyoderma gangrenosum.
As a tumor necrosis factor-alpha antagonist, infliximab is approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis and Crohn's disease. Infliximab has been used to treat a variety of dermatological diseases. Among these is pyoderma gangrenosum (PG), an un...
| Publicado en: | Wounds: A Compendium of Clinical Research & Practice Vol. 15; no. 2; pp. 49 - 54 |
|---|---|
| Autores principales: | , , , |
| Formato: | pictorial research tables/charts Journal Article |
| Publicado: |
HMP Global
2003 Feb Supplement
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106710142&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 106710142 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10447946 YZM jtl: Wounds: A Compendium of Clinical Research & Practice issn: 10447946 maglogo: N pubinfo: dt: 2003 Feb Supplement vid: 15 iid: 2 pid: 20465 pub: HMP Global place: Malvern, Pennsylvania artinfo: ui: 106710142 106710142 2004042336 106710142 ppf: 49 ppct: 5 formats: tig: atl: Infliximab: a treatment option for ulcerative pyoderma gangrenosum. aug: au: Geren SM Kerdel FA Falabella AF Kirsner RS affil: Dept of Dermatology and Cutaneous Surgery, Veterans Affairs Medical Center, University of Miami School of Medicine, Miami, FL sug: subj: Infliximab Therapeutic Use Pyoderma Gangrenosum Drug Therapy Adult Aged, 80 and Over Female Infliximab Administration and Dosage Infliximab Adverse Effects Infusions, Intravenous Male Middle Age Record Review Retrospective Design Treatment Outcomes Human Adult: 19-44 years Aged, 80 & over Middle Aged: 45-64 years Female Male ab: As a tumor necrosis factor-alpha antagonist, infliximab is approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis and Crohn's disease. Infliximab has been used to treat a variety of dermatological diseases. Among these is pyoderma gangrenosum (PG), an uncommon inflammatory disorder characterized by painful skin ulcers. Often treated with corticosteroids, antibiotics with anti-inflammatory properties, and/or immunosuppressive medications, PG may be difficult to treat. The authors performed a retrospective analysis of patients with refractory PG treated with infliximab at a dose of 5mg/kg. Five patients were treated. Infliximab was efficacious in all, with healing of 12 of 13 ulcers in a mean time of 12.2 weeks. Patients received a range of one to three infusions (mean 1.8). In conclusion, infliximab is a treatment option for PG. pubtype: Periodical doctype: pictorial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|